Brown Advisory Inc. Acquires 7,818 Shares of Cencora, Inc. (NYSE:COR)

Brown Advisory Inc. boosted its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 8.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 96,503 shares of the company's stock after buying an additional 7,818 shares during the period. Brown Advisory Inc.'s holdings in Cencora were worth $21,682,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of COR. Banque Transatlantique SA bought a new position in Cencora in the 4th quarter valued at approximately $29,000. Bellevue Group AG raised its holdings in Cencora by 7.6% during the 4th quarter. Bellevue Group AG now owns 77,522 shares of the company's stock worth $17,418,000 after purchasing an additional 5,469 shares during the last quarter. Bank of America Corp DE raised its holdings in Cencora by 62.3% during the 4th quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock worth $1,166,944,000 after purchasing an additional 1,994,256 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Cencora by 96.4% during the 4th quarter. Ameriprise Financial Inc. now owns 541,881 shares of the company's stock worth $121,747,000 after purchasing an additional 266,011 shares during the last quarter. Finally, Alteri Wealth LLC bought a new position in Cencora during the 4th quarter worth approximately $275,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total value of $3,928,916.78. Following the completion of the transaction, the chairman now directly owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares of the company's stock, valued at $5,241,249.24. The trade was a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,223 shares of company stock worth $13,580,967. 10.80% of the stock is owned by company insiders.

Cencora Stock Down 2.4%

Cencora stock traded down $6.72 on Monday, hitting $276.28. 1,231,542 shares of the stock traded hands, compared to its average volume of 1,525,751. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a market cap of $53.58 billion, a P/E ratio of 39.31, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The business's fifty day simple moving average is $276.48 and its 200 day simple moving average is $253.57. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. During the same quarter in the previous year, the firm earned $3.80 EPS. Cencora's quarterly revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.80%. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Analysts Set New Price Targets

COR has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Morgan Stanley set a $288.00 price objective on shares of Cencora in a report on Tuesday, April 15th. Citigroup lifted their price objective on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Robert W. Baird boosted their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $301.18.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.